Stockscreener 앱 받기
1.54
4.94%
-0.08
시장 영업 전:
1.55
0.01
+0.65%
Bioxcel Therapeutics Inc 주식(BTAI)의 최신 뉴스
Bioxcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for Igalmi in the At-Home Setting - marketscreener.com
BioXcel Therapeutics (BTAI) Advances with Igalmi for At-Home Use - GuruFocus
BioXcel Highlights IGALMI At-Home Acute Agitation Opportunity - TipRanks
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting - The Manila Times
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI in the At-Home Setting - Bitget
BioXcel Therapeutics Completes Market Assessment for IGALMI - TradingView
What earnings margins imply for BioXcel Therapeutics Inc. (BX20) stockWeekly Loss Report & Stock Portfolio Risk Management - mfd.ru
Aug Selloffs: What are the risks of holding BioXcel Therapeutics Inc.Weekly Volume Report & Consistent Growth Stock Picks - mfd.ru
BioXcel Therapeutics announces milestone and retention bonuses for key executives - Investing.com
BioXcel sets milestone bonuses amid pivotal IGALMI review - TipRanks
CEO Moves: What is GMFIWs 5 year growth outlookTrade Entry Report & Community Supported Trade Ideas - baoquankhu1.vn
Rate Hike: Is BioXcel Therapeutics Inc gaining market share2025 Key Highlights & Growth Focused Entry Reports - baoquankhu1.vn
Movement Recap: Is BioXcel Therapeutics Inc. stock a falling knife or bargain buyJuly 2025 Opening Moves & Stepwise Trade Signal Guides - mfd.ru
BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial - Law360
BioXcel Therapeutics submits sNDA for at-home use of IGALMI By Investing.com - Investing.com South Africa
BioXcel Therapeutics (BTAI) Advances Igalmi's Reach with FDA Sub - GuruFocus
BioXcel Therapeutics submits application to expand IGALMI use for at-home treatment - Investing.com Nigeria
BioXcel seeks FDA approval for at-home IGALMI use - TipRanks
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting - The Manila Times
BioXcel Therapeutics Submits Supplemental NDA To US FDA For IGALMI® At-Home Label Expansion - TradingView
BioXcel Therapeutics submits sNDA for at-home use of IGALMI - Investing.com
BioXcel Therapeutics Submits sNDA for IGALMI® At-Home Use - TradingView
What are the risks of holding BioXcel Therapeutics Inc.Weekly Trade Report & Capital Protection Trading Alerts - bollywoodhelpline.com
How BioXcel Therapeutics Inc. (BX20) stock moves on employment data2025 Fundamental Recap & Weekly Breakout Watchlists - bollywoodhelpline.com
Ag Plus, Inc. - Ag Plus, Inc.
Palmetto Grain Brokerage - Palmetto Grain Brokerage
1 Top Penny Stock to Watch Now - Yahoo Finance
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
BioXcel adds chief commercial officer as it prepares to expand agitation drug IGALMI’s reach - Hartford Business Journal
VIX Spike: Can BioXcel Therapeutics Inc. stock maintain growth trajectoryTrade Entry Report & Smart Swing Trading Alerts - Bộ Nội Vụ
BioXcel Therapeutics Appoints Mark Pavao as Interim Chief Commercial Officer - citybiz
Returns Recap: Is BioXcel Therapeutics Inc benefiting from interest rate changesJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
BioXcel Therapeutics names interim CCO amid IGALMI expansion - TipRanks
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting - The Manila Times
BioXcel Therapeutics Announces Interim Chief Commercial Officer - TradingView
Drugmaker taps veteran to pursue at-home treatment for bipolar agitation - Stock Titan
Published on: 2026-01-09 03:25:25 - Улправда
Oklahoma City NewsThe Oklahoman - FinancialContent
Trend Review: How institutional buying supports BioXcel Therapeutics Inc. stockJuly 2025 Spike Watch & Breakout Confirmation Trade Signals - Улправда
Will BioXcel Therapeutics Inc. stock attract ESG investorsQuarterly Portfolio Summary & Consistent Profit Alerts - ulpravda.ru
Is BioXcel Therapeutics Inc. (BX20) stock undervalued historicallyJuly 2025 Breakouts & Fast Moving Stock Trade Plans - Улправда
What insider trading reveals about BioXcel Therapeutics Inc. stockTrade Risk Assessment & Fast Entry Momentum Alerts - ulpravda.ru
How robust is BioXcel Therapeutics Inc. (BX20) stock financial positionMACD Histogram Signals & Maximize Returns With Insights - ulpravda.ru
BioXcel Seeks FDA Nod For At-Home Use Of IGALMI In Bipolar And Schizophrenia Agitation - Nasdaq
BioXcel plans FDA submission for at-home agitation treatment - Investing.com
BioXcel plans FDA submission for at-home agitation treatment By Investing.com - Investing.com Nigeria
BTAI FinancialsIncome Statement - Quiver Quantitative
BioXcel Therapeutics, Inc. Plans Supplemental NDA Submission for IGALMI® Approval for At-Home Use in Treating Agitation Associated with Bipolar Disorders and Schizophrenia - Quiver Quantitative
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI - Chartmill
BioXcel Therapeutics enacts 1-for-16 reverse stock split - MSN
BioXcel Therapeutics (BTAI) price target decreased by 26.17% to 16.12 - MSN
Will BioXcel Therapeutics Inc. stock see insider buying2025 Sector Review & Real-Time Chart Breakout Alerts - Bộ Nội Vụ
Vipin Agarwal Net Worth (2025) - GuruFocus
Is BioXcel Therapeutics Stock Built to Withstand More Downside? - Trefis
What MACD trends signal for BioXcel Therapeutics Inc. (BX20) stockWeekly Market Report & Community Driven Trade Alerts - Улправда
EPS Watch: How robust is BioXcel Therapeutics Inc. (BX20) stock financial position2025 Earnings Surprises & AI Powered Market Entry Strategies - Улправда
0.70%
10.43%
자본화:
|
볼륨(24시간):